Background: the pandemic of COVID-19 have forced the health system to incorporate many antiviral drugs to the medical field applications. The urgent need for a safe and effective treatment has encouraged the researchers to initiate clinical trials evaluating the efficacy of many drugs targeting virus. Aim: This trial compared the effectiveness of the combination of nitazoxanide, ribavirin and [ivermectin](https://www.drugs.com/mtm/ivermectin.html) plus Zinc vs. those receiving remdesivir or favipiravir treatment. Subject and Methods: This non-randomized controlled trial included 108 hospitalized patients receive treatment classified into 3 groups NRIZ group, favipiravir group, and remdesivir group. all of them confirmed case by positive RT-PCR of nasopharyngeal swab. Results: this trial shows that there are no statistical differences among the 3 groups as regard age, sex, Severity, Comorbidities, mode of O2 intake and outcome except for the length of stay at hospital was lower in NIRZ group in Pairwise comparison between NRIZ group vs. Remdesivir group (P 0.03). Conclusion: This trial concluded that NRIZ combination therapy not inferior to neither favipiravir nor remdesivir.